Literature DB >> 12529664

Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia.

C H Seedhouse1, E P Das-Gupta, N H Russell.   

Abstract

The hMLH1 and hMSH2 genes are involved in the DNA mismatch repair (MMR) pathway. Defects in either of these genes have been associated with genetic instability in a wide variety of malignancies. A molecular mechanism involved in aberrant MMR gene expression is the epigenetic silencing of transcription by promoter methylation. The importance of MMR promoter methylation in leukemia is presently unclear and we have therefore undertaken a detailed analysis of the promoter regions of hMLH1 and hMSH2 using the technique of bisulfite genomic sequencing. DNA from 55 patients with acute myeloid leukemia (AML) including 23 patients with therapy-related AML (t-AML) have been analyzed. Two patients with de novo AML demonstrated extensive methylation throughout the whole hMLH1 region sequenced, one of whom had previously shown widespread genetic instability, measured as microsatellite instability (MSI). However methylation of hMLH1 was not found in t-AML which has previously been associated with MSI. In addition, methylation was seen at a restricted region of the hMLH1 promoter in both AML patients and healthy controls. The significance of this methylated region of the hMLH1 promoter is uncertain, however, our results confirm that in some patients with AML extensive methylation of hMLH1, but not of hMSH2 may occur, and as is the case in solid tumors this can be associated with the presence of a defective DNA mismatch repair pathway resulting in MSI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12529664     DOI: 10.1038/sj.leu.2402747

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

Review 1.  Epigenetic changes of DNA repair genes in cancer.

Authors:  Christoph Lahtz; Gerd P Pfeifer
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

Review 2.  Novel agents for the treatment of childhood acute leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Ther Adv Hematol       Date:  2015-04

Review 3.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 4.  Epigenetics in acute myeloid leukemia.

Authors:  Christoph Plass; Christopher Oakes; William Blum; Guido Marcucci
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

5.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

Review 6.  Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

Review 7.  Epigenetic regulation of DNA repair machinery in Helicobacter pylori-induced gastric carcinogenesis.

Authors:  Juliana Carvalho Santos; Marcelo Lima Ribeiro
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

8.  Therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  Smita Bhatia
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

Review 9.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

Review 10.  Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.

Authors:  Patrick Brown; Franklin O Smith
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.